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Introduction
MicroRNAs (miRNAs) are an evolutionarily conserved 
class of small, approximately 22-nucleotide non-coding 
RNAs that decrease gene expression post-transcrip-
tionally in a sequence-speciﬁ  c manner. Most miRNAs are 
transcribed in the nucleus by RNA polymerase II 
(although some miRNAs are also transcribed by RNA 
polymerase III [1]) as long primary transcripts (pri-
miRNAs) that undergo processing by Drosha and 
DGCR8, resulting in an approximately 70-nucleotide 
stem-loop RNA (pre-miRNA). Pre-miRNAs are subse-
quently exported to the cytoplasm via Exportin 5 and 
cleaved by Dicer, giving rise to approximately 
22-nucleotide RNA duplexes. Th   e strand with decreased 
base-pairing at its 5´ end is then selected to function as a 
mature miRNA, while the other strand (also referred to 
as the passenger strand) is typically degraded [2,3]. Th  e 
mature miRNA associates with Argonautes and other 
proteins to form the RNA-induced silencing complex 
(miRISC), which then binds to target mRNAs via partial 
complementarity. Many transcription factors that regu  late 
mRNA transcription also control miRNA biogenesis. 
Although transcription plays a major role in miRNA bio-
genesis, additional mechanisms, such as DNA methy  la-
tion, can also regulate miRNA expression [4]. Mammalian 
miRNAs predominantly act by binding to the 3´ un-
translated region (UTR) of cognate mRNAs. However, 
there is growing evidence that they can also downregulate 
the expression of some genes by base-pairing to the 
coding region [5-8] or the 5´ UTR of some mRNAs [9].
Initially, miRNAs were thought to function mainly by 
suppressing mRNA translation [10]. However, two recent 
studies combined proteomics and microarrays to reveal 
that changes in protein expression mediated by a miRNA 
are usually associated with altered mRNA expression, 
suggesting that mRNA degradation may be the major 
component of mammalian miRNA repression [11,12]. 
Although most studies suggest that miRNAs negatively 
regulate gene expression by base-pairing to the 3´ UTR, a 
few recent examples have shown that miRNAs can also 
upregulate the translation of their target mRNAs [13].
According to miRBase release 14 (September 2009), 
more than 700 human miRNAs have been identiﬁ  ed [14]. 
Regardless of the mechanism by which they regulate gene 
expression, each miRNA can potentially regulate the 
expression of hundreds of genes and a single transcript 
can be targeted by multiple miRNAs to concurrently 
downregulate multiple proteins in the same pathway. In 
fact, almost one-third of the protein-coding genes are 
susceptible to miRNA regulation [15] and, as a conse-
quence, many miRNAs seem to play pivotal roles in 
impor  tant biological processes, including cellular 
prolifera tion,  diﬀ   erentiation and apoptosis [16]. Not 
surprisingly, aberrant miRNA expression is a hallmark of 
several diseases, cancer in particular [17,18]. In this 
review we will focus on recent advances on the functions 
of miRNAs in breast tumor development and metastasis. 
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cancer-associated miRNAs, we have built a direct gene 
interaction network to illustrate how the targets of these 
miRNAs interact with each other via protein-protein or 
protein-DNA interactions. Th  is approach reveals that 
many genes involved in breast cancer are embedded in a 
miRNA network that controls their expression leading to 
breast cancer pathogenesis.
MicroRNAs as critical regulators of tumorigenesis
In normal cells, miRNAs control normal rates of cellular 
growth, proliferation, diﬀ  erentiation and apoptosis. Since 
miRNAs inhibit cell cycle progression and drive terminal 
diﬀ   erentiation, downregulation of some miRNAs may 
play an important role in the development or progression 
of cancer [19]. In this context, at least three observations 
early in the history of miRNAs suggested their potential 
role in cancer. First, the earliest miRNAs discovered in 
Caenorhabditis elegans and Drosophila were shown to 
regulate cellular proliferation and apoptosis [20,21], 
suggesting that deregulation of these miRNAs may lead 
to proliferative diseases. Second, many miRNA loci 
frequently map to genomic regions that are commonly 
ampliﬁ  ed or deleted in various human cancers [19,22-
25]. Th  ird, tumor cell lines and malignant tumors were 
found to have widespread deregulation of miRNA expres-
sion [23,26,27]. Furthermore, expression of some miRNAs 
correlated with diverse clinicopathological parameters 
[23,28,29] and prognosis [30,31]. Taken together, these 
ﬁ  ndings highlighted a potential role of miRNAs as new 
diagnostic or prognostic biomarkers. Moreover, the 
evidence that speciﬁ  c miRNAs have tumor suppressor 
and oncogenic functions makes them novel targets for 
cancer therapy.
A global decrease in miRNA expression has been 
observed in human cancers, suggesting that most 
miRNAs may act as tumor suppressors [27]. Furthermore, 
poorly diﬀ  erentiated tumors have lower miRNA levels 
compared to more diﬀ  erentiated tumors, indicating that 
global changes in miRNA expression may indicate the 
degree of cellular diﬀ   erentiation. In support of this 
hypothesis, a recent study showed that most miRNAs 
were expressed at lower levels in human tumor-derived 
cell lines compared to the corresponding tissue [26]. 
However, it remained unclear if the reduced miRNA 
expression was the cause or the consequence of 
malignant transformation. Remarkably, another study 
demonstrated that the global loss in miRNA expression 
in cancer promoted tumorigenesis [32]. Global loss of 
miRNA expression achieved by knockdown of Drosha 
and Dicer, two proteins essential for miRNA biogenesis, 
enhanced cellular growth in vitro. When these cells were 
injected into nude mice, they formed faster-growing and 
more invasive tumors. Taken together, these results 
suggest that genome-wide loss of miRNAs enhances 
tumorigenesis. However, it remains to be seen if the loss 
of all miRNAs or only a subgroup of key tumor sup-
pressor miRNAs is the key event that promotes 
tumorigenesis.
Roles of microRNAs in breast cancer
Over the past few years, miRNA proﬁ  ling studies have 
led to the identiﬁ  cation of miRNAs that are aberrantly 
expressed in human breast cancer. Th   e function of only a 
handful of these miRNAs in breast cancer has been 
investigated. As in other cancers, some miRNAs can 
function as tumor suppressors and other miRNAs as 
oncogenes. Th  us, tumor formation may arise from a 
reduction or deletion of a tumor suppressor miRNA and/
or ampliﬁ   cation or overexpression of an oncogenic 
miRNA. In addition, tumor metastasis may be promoted 
by enhanced expression of prometastatic and/or 
downregulation of antimetastatic miRNAs. Th  e  functions 
of these miRNAs in breast tumor progression and 
metastasis are discussed below.
Tumor suppressor miRNAs
In this section we discuss recent ﬁ  ndings on seven well-
known miRNAs that inhibit breast tumor formation and/
or metastasis (Table 1).
miR-206
A potential role of miR-206 in suppressing breast cancer 
was ﬁ  rst identiﬁ  ed by employing miRNA microarrays to 
compare miRNA expression between normal and breast 
cancer tissues [28]. miR-206 was upregulated in estrogen 
receptor (ER)α-negative breast cancers, suggesting a role 
of miR-206 in regulation of the estrogen receptor gene 
ERα ( ESR1). Indeed, miR-206 was recently shown to 
inhibit the expression of ESR1 mRNA through two 
binding sites in the ESR1 3´ UTR [33]. Th  e latter study 
also showed that miR-206 expression was strongly 
repressed by ERα agonists, but not by an ERβ agonist or 
progesterone, suggesting the existence of a feedback loop. 
Another study showed that miR-206 expression 
decreased in ERα-positive human breast cancer tissues 
and that miR-206 suppresses ESR1 expression and 
inhibits growth of MCF7 breast cancer cells. In addition 
to miR-206, the authors found that ESR1 mRNA was a 
direct target of miR-18a, miR-18b, miR-193b and miR-
302c in breast cancer cells [34]. Moreover, miR-18a, miR-
18b, miR-193b, miR-206 and miR-302c were also shown 
to induce cell cycle arrest and to inhibit estrogen-induced 
proliferation, with inhibition levels comparable to those 
achieved by ERα small interfering RNA (siRNA). Since 
dysregulation of ERα expression is a hallmark of most 
human breast cancers, these studies provide important 
insights into the molecular mechanisms that lead to 
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for miR-206 in breast cancer was further substantiated by 
the recent demonstration that miR-206, miR-335 and 
miR-126 are potently downregulated in metastatic breast 
cancer cells compared to parental cells [35]. Importantly, 
restoring the expression of these three miRNAs reduced 
their invasive capacity. Th   e authors identiﬁ  ed four direct 
targets of miR-335, PTPRN2, MERTK, TNC and SOX4; 
among them, TNC (encoding an extracellular matrix 
component) and SOX4 (encoding a transcription factor 
that is involved in tumorigenesis) were shown to be 
functional targets implicated in metastasis. Restoring 
miR-206 expression in metastatic cells did not inﬂ  uence 
their proliferation or sensitivity to apoptosis, but altered 
cellular morphology, possibly contributing to a decrease 
in cell motility that could limit the migration of 
metastatic cells [35]. Th  ese  ﬁ  ndings suggest that miR-206 
could be a novel candidate for breast cancer therapy.
miR-17-5p
miR-17-5p, also known as miR-91, is located on chromo-
some 13q31, a genomic region that undergoes loss of 
heterozygosity in multiple cancers, including breast 
cancer [36]. Th  e oncogene AIB1 (ampliﬁ   ed in breast 
cancer) is a direct target of miR-17-5p [37]. Th  e  protein 
encoded by the AIB1 gene is a steroid receptor co-
activator that enhances the transcriptional activity of 
ERα, E2F1 (which is also directly regulated by miR-17-5p) 
and other transcription factor genes. miR-17-5p represses 
the translation of AIB1 mRNA, thereby inhibiting the 
function of E2F1 and ERα. Downregulation of AIB1 by 
miR-17-5p results in the suppression of estrogen-
stimulated proliferation and estrogen/ER-independent 
breast cancer cell proliferation [37]. In breast cancer cells, 
the gene cyclin D1 (CCND1), which is overexpressed in 
approximately 50% of human cancers, was recently 
identiﬁ  ed as a direct target of miR-17-5p [38]. miR-17-5p 
inhibits the proliferation of breast cancer cells by 
suppressing cyclin D1 protein synthesis and this eﬀ  ect 
was abrogated by a CCND1 siRNA in cyclin D1-deﬁ  cient 
breast cancer cells. Th   is study also identiﬁ  ed a regulatory 
mechanism in which cyclin D1 induces miR-17-5p 
expression, thus providing a negative feedback loop that 
limits cyclin D1 expression.
miR-125a and miR-125b
Th  e HER2 ( ERBB2) gene encodes a member of the 
epidermal growth factor receptor family of tyrosine 
kinases. Th   is protein has no ligand-binding domain of its 
own and cannot, therefore, bind growth factors. How-
ever, it binds tightly to other ligand-bound epidermal 
growth factor receptor family members to form a 
heterodimer, stabilizing ligand-binding activity and 
enhancing kinase-mediated activation of downstream 
signaling pathways, such as those involving mitogen-
activated protein kinase (MAPK) and phosphatidyl-
inositol-3 kinase [39]. Ampliﬁ  cation and/or over  expres-
sion of this gene has been reported in numerous cancers, 
including breast tumors. miR-125a and miR-125b are 
downregulated in HER2-ampliﬁ   ed and HER2-over-
expressing breast cancers [40]. Th  ese two miRNAs are 
potential tumor suppressors and their overexpression in 
SKBR3 cells (a HER2-dependent human breast cancer 
cell line) suppresses HER2 and HER3 mRNA and protein 
levels, leading to a reduction in anchorage-dependent 
growth, cell motility, and invasiveness [41]. However, this 
inﬂ   uence was subtle in non-transformed HER2-
independent breast cancer cells (MCF10A).
Table 1. miRNAs and their targets in breast cancer cells
miRNA Target  Functional  pathway  Reference
Tumor suppressor miRNAs
 miR-206  ESR1  ER signaling  [28,33]
 miR-17-5p  AIB1, CCND1, E2F1  Proliferation [37,38]
 miR-125a,  b  HER2, HER3  Anchorage-dependent growth  [40,41]
 miR-200  BMI1, ZEB1, ZEB2  TGF-β signaling  [47,52,54]
 let-7  H-RAS, HMGA2, LIN28, PEBP1  Proliferation, diff  erentiation  [73-75]
 miR-34a  CCND1, CDK6, E2F3, MYC  DNA damage, proliferation  [76-78]
 miR-31  FZD3, ITGA5, M-RIP, MMP16, RDX, RHOA  Metastasis [61]
Oncogenic miRNAs
 miR-21  BCL-2, TPM1, PDCD4, PTEN, MASPIN  Apoptosis [64-67]
 miR-155  RHOA  TGF-β signaling  [68]
 miR-10b  HOXD10  Metastasis [69]
 miR-373/520c  CD44  Metastasis [79]
miRNAs and their targets in breast cancer. Several studies have identifi  ed altered miRNA expression profi  les in breast cancer. The loss of several tumor suppressor 
miRNAs and overexpression of oncogenic miRNAs leads to loss of regulation of several cellular functions that may be involved in breast cancer pathogenesis.
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Invasion and metastasis are the hallmarks of malignant 
tumor progression. Increasing evidence indicates that 
activation of the embryonic program ‘epithelial-mesen-
chymal transition’ (EMT) promotes these processes by 
allowing detachment of cells from each other, thereby 
increasing tumor cell mobility and dissemination [42]. In 
recent years, it has become evident that aberrant 
activation of EMT is responsible for the malignant 
transformation of many human cancers. EMT is activated 
by EMT-inducing transcriptional repressors, including 
members of the Snail family and the ZFH family of 
transcription factors [43]. Th  ese proteins inhibit the 
transcription of epithelial genes, such as that encoding 
E-cadherin. Recently, ZEB1, a ZFH-family member, was 
shown to be a crucial EMT activator in human cancers, 
including breast cancer [44,45], and to promote 
metastasis of tumor cells in a mouse xenograft model 
[46]. Th   e miR-200 family of miRNAs has been shown to 
be crucial inducers of an epithelial phenotype by 
suppressing the expression of the EMT inducers ZEB1 
and ZEB2. Gregory et al. [47] induced EMT in MDCK 
cells (human Madin Darby canine kidney epithelial cells) 
either by transforming growth factor (TGF)-β or by 
stable expression of the tyrosine phosphatase Pez. Th  e 
authors found that all ﬁ   ve members of the miR-200 
family, which are clustered in two genomic locations, 
were downregulated upon TGF-β-induced EMT. Func-
tional studies showed that inhibition of miR-200a, b, and 
c in MDCK cells triggered TGF-β-independent EMT that 
was associated with increased expression of vimentin, 
ﬁ  bronectin and N-cadherin, and downregulation of E-
cadherin. Conversely, overexpression of miR-200 family 
members in mesenchymal cells initiated mesenchymal-
to-epithelial transition. Luciferase reporter assays under 
the control of ZEB1 and ZEB2 3´ UTR veriﬁ  ed that these 
genes are direct targets of the miR-200 family. Th  e 
clinical relevance of these ﬁ  ndings was further suggested 
by additional analyses of human breast cancer tissues 
showing that a decrease in miRNA-200 family miRNAs 
was associated with highly aggressive, metaplastic breast 
tumors. Th  eir  ﬁ  nding that ZEB1 and ZEB2 expression is 
controlled by the miR-200 family suggests that down-
regulation of these miRNAs is an essential early step in 
tumor metastasis.
Similar overlapping results were obtained in another 
study, which employed the NCI-60 panel of cell lines, 
representing 60 cell lines of diﬀ  erent human tumor types 
[48]. By using two markers, the authors divided the panel 
into two major groups, characterized either by an 
epithelial phenotype (marked by E-cadherin) or a 
mesenchymal phenotype (marked by vimentin) and 
found that the miR-200 family was strongly associated 
with the epithelial phenotype. Overexpression of miR-200 
induced epithelial diﬀ   erentiation in undiﬀ  erentiated 
breast cancer cells (MDA-MB231) whereas antagonizing 
it induced an EMT phenotype in the colorectal cancer 
cell line HCT116. ZEB1 and ZEB2 were again detected as 
targets of the miR-200 family members. Th   ese and other 
recent reports on the miR-200 family [49,50] add 
important miRNAs to the growing list of tumor-asso-
ciated miRNAs. Furthermore, a recent study showed that 
the expression of the miR-200 family was decreased by 
Akt2, suggesting that, in many cases, breast cancer 
metastasis may be under the control of the Akt-miR-200-
E-cadherin pathway [51]. Interestingly, a recent study 
showed that expression of miR-200 unexpectedly en-
hanced macroscopic metastases in mouse breast cancer 
cell lines [52]. Th   eir results suggest that, for some tumors, 
tumor colonization at metastatic sites might be enhanced 
by mesenchymal-to-epithelial transition and that the 
epithelial nature of a tumor may not predict metastatic 
outcome. Although this paper is the ﬁ  rst to show the 
direct enhancement of metastasis by the miR-200 family, 
changes in miR-200 family levels have been associated 
with enhanced tumorigenesis. For instance, the miR-200 
family is upregulated in human ovarian cancers 
compared to normal ovarian tissue [29]. Moreover, over-
expression of the miR-200 family signiﬁ  cantly correlates 
with decreased survival. Patients with ovarian tumors 
with high miR-200a expression have been shown to have 
approximately 50% decrease in median survival time 
compared to those lacking signiﬁ  cant miR-200a expres-
sion. Furthermore, the region on chromosome 1 that 
encodes the miR-200 cluster was also found to be 
ampliﬁ  ed in several epithelial cancers - ovarian cancer, 
breast cancer and melanoma [53]. A new study [54] 
revealed the roles of three miRNA clusters (miR-200c-141, 
miR-200b-200a-429 and miR-183-96-182) in the 
regulation of self-renewal in cancer stem cells and normal 
stem cells. Th   ese miRNAs were downregulated in human 
breast cancer stem cells, normal human and mouse 
mammary stem/progenitor cells as well as embryonal 
carcinoma cells. Th   e authors provided evidence that BMI1 
(a gene that promotes stem cell self-renewal) is speciﬁ  cally 
inhibited by these miRNAs and showed that ectopic 
overexpression of miR-200c in embryonal carcinoma cells 
resulted in growth retardation and neural diﬀ  erentiation 
and suppressed tumorigenicity of breast cancer stem cells 
in vivo [55]. Taken together, these studies suggest that 
miRNAs of the miR-200 family play important roles in 
regulating tumor progression and metastasis.
let-7 family
let-7, one of the founding members of the miRNA family, 
was originally discovered to play a role in the develop-
mental timing of C. elegans [56] and is conserved 
throughout the animal phyla. let-7 is poorly expressed or 
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hematologic malignancies and solid tumors suggest that 
each includes minor populations of cells that are capable 
of tumor initiation [57]. Th  ese tumor-initiating cells 
(T-ICs) have properties of tumor stem cells and can 
undergo asymmetric cell division and self renewal. T-ICs 
comprise only a minor fraction among the bulk of the 
more diﬀ   erentiated cells in the tumor.  Based on the 
cancer stem cell hypothesis, T-ICs are responsible for the 
initiation, progression, metastasis and resistance to 
therapy. Breast T-ICs (BT-ICs) can be enriched by 
purifying CD44+CD24–/low cells by sorting or by purifying 
spherical clusters of self-replicating cells (mammo-
spheres) from cell suspensions.
A recent study compared miRNA expression in self-
renewing and diﬀ  erentiated cells from breast cancer lines 
and found that the expression of let-7 was strongly 
reduced in BT-ICs and increased with diﬀ  erentiation 
[58]. Introducing let-7 in BT-ICs reduced their prolifera-
tive capacity, their ability to form mammo  spheres and 
tumor formation and metastasis in vivo. Conversely, 
knocking down let-7 enhanced self-renewal of non-T-ICs 
in vitro. Known oncogenic targets of let-7, such as H-RAS 
and  HMGA2, were downregulated by let-7 over-
expression. Silencing H-RAS in a BT-IC-enriched cell line 
reduced self-renewal but had no eﬀ  ect on diﬀ  erentiation, 
while knocking down HMGA2 enhanced diﬀ  erentiation 
but did not aﬀ  ect self-renewal. Th   eir results suggest that 
let-7 regulates multiple BT-IC stem cell-like properties 
and that let-7 may oﬀ  er a unique opportunity to attack 
tumor stem cells using therapeutic RNA. Delivery of the 
let-7 miRNA to tumors could potentially deplete stem 
cells by inducing cellular diﬀ  erentiation.
A recent report linked the protein RKIP (Raf kinase 
inhibitory protein) to let-7 and breast cancer metastasis. 
RKIP (also called PEBP1) inhibits MAPK, G protein-
coupled receptor kinase-2, and NF-κB signaling cascades 
[59]. Th   e authors found that RKIP inhibited invasion by 
metastatic breast cancer cells and repressed breast tumor 
cell intravasation and bone metastasis in a mouse model. 
Inhibition of MAPK decreased trans  cription of LIN28 by 
MYC; in turn, downregulation of LIN28, an inhibitor of 
let-7 biogenesis, enhanced let-7 expression in breast 
cancer cells leading to decreased expression of HMGA2, 
a chromatin-remodeling protein that activates pro-
invasive and prometastatic genes, including Snail. 
Collectively, their ﬁ  ndings indicate that RKIP suppresses 
invasion and metastasis via a signaling cascade that 
involves MAPK, MYC, LIN28, let-7, and downstream 
let-7 targets such as HMGA2.
miR-34a
miR-34a is one of several miRNAs that are downregulated 
in multiple cancers [26] and has been shown to be 
trans  criptionally regulated by p53. In the context of 
breast cancer, only one study [60] has shown that miR-
34a levels were lower in triple negative and mesenchymal 
breast cancer cell lines compared with normal epithelial 
lines and HER-2+ lines. Th  e authors propose that p53 
muta  tions in these subtypes of breast cancer might 
contribute to low miR-34a expression. To elucidate the 
relationship between miR-34a and radiosensitivity in 
these cells, the authors compared the sensitivity of a 
normal breast epithelial line (HMEC), a HER-2+ line 
(UACC812) and a mesenchymal line (MDA-MB-231) 
and found that the MDA-MB-231 cell line (with low miR-
34a levels) was signiﬁ  cantly more sensitive to radiation 
than the HMECs or UACC-812 (with high miR-34a 
levels). Increasing the levels of miR-34a protected the 
MDA-MB-231 cells from radiation-induced cell death, 
and downregulating it had the converse eﬀ  ect.  Th  ese 
results show that miR-34a is necessary for the survival of 
MDA-MB-231 cells from non-apoptotic cell death and 
suggest that miR-34a may have therapeutic potential in 
breast cancers, since antagonizing miR-34a increases the 
sensitivity of breast cancer cells towards radiation.
miR-31
miR-31 was recently shown to prevent metastasis at 
multiple steps by inhibiting the expression of prometa-
static genes [61]. miR-31 is expressed in normal breast 
cells and its abundance was shown to be dependent on 
the metastatic state of the tumor. It is moderately 
decreased in non-metastatic breast cancer cell lines and 
is almost undetectable in metastatic mouse and human 
breast cancer cell lines. Importantly, the authors 
demonstrated that introducing miR-31 in metastatic 
breast cancer cells suppressed metastasis-related func-
tions (motility, invasion and resistance to anoikis) in vitro 
and metastasis in vivo. Notably, they found that although 
miR-31 over-expressing breast cancer cells formed larger 
and more proliferative tumors, these tumors were well 
encapsulated and thereby less invasive, suggesting that 
miR-31 inhibits metastasis in the early stages of the 
metastasis cascade. Injecting miR-31 overexpressing cells 
directly into the circulation impeded the ability of the 
cells to survive and form secondary tumors in the lung, 
suggesting that miR-31 inhibits metastasis at multiple 
steps of the metastatic cascade. Conversely, inhibition of 
miR-31 function increased invasiveness and promoted 
metastasis  in vivo. To identify functionally relevant 
mRNA targets of miR-31 through which it might exert its 
antimetastatic eﬀ   ects, the authors employed Gene 
Ontology analysis on the putative targets of miR-31 
predicted by the miRNA-target prediction algorithms 
TargetScan and PicTar. Using this approach, they 
validated six targets of miR-31 in human breast cancer 
cells: frizzled3 (Fzd3), integrin α-5 (ITGA5), myosin 
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metallopeptidase 16 (MMP16), radixin (RDX) and the ras 
homolog gene family member A (RhoA). Interestingly, 
they showed that re-expression of three of these genes, 
ITGA5, RDX and RhoA, in metastatic breast cancer cells 
abrogated the motility defects and reversed the impaired 
invasion and anoikis resistance defects conferred by 
miR-31, suggesting that these three genes are functionally 
important targets of miR-31. Taken together, their 
ﬁ   ndings demonstrate that miR-31 may also be an 
attractive therapeutic target for breast cancer as it exerts 
its antimetastatic eﬀ   ect by targeting multiple pro-
metastatic genes of the metastasis cascade.
Oncogenic miRNAs
Th  e function of four well-established oncogenic and/or 
metastasis promoting miRNAs (Table  1) are discussed 
below.
miR-21
miR-21 has been found to be consistently overexpressed 
in many tumors, including breast cancer [28,62]. Consis-
tent with these ﬁ  ndings, miR-21 was also shown to be 
highly upregulated in breast tumors compared to the 
matched normal breast tissues among 157 human 
miRNAs analyzed by real-time RT-PCR arrays [63], 
suggesting that miR-21 may function as an oncogene. Th  e 
latter study also examined the oncogenic role of miR-21 
in cell culture as well as in mouse xenografts. Although 
the inﬂ  uence of knocking down miR-21 on cell survival 
was marginal (25% decrease), the authors found that this 
growth inhibition increased when the transfected MCF-7 
cells were treated with the anticancer drug topotecan, 
suggesting that suppression of miR-21 can sensitize 
tumor cells to anticancer agents. To further investigate 
whether suppression of miR-21 alone inﬂ  uences tumori-
genesis, they antagonized miR-21 in MCF-7 cells and 
then injected them into mammary pads of female nude 
mice. Tumors derived from MCF-7 cells transfected with 
anti-miR-21 were one-half the size of those derived from 
the cells transfected with the negative control, while anti-
Ki-67 indicated that the reduced tumor growth was likely 
due to a lower proliferation caused by anti-miR-21. Th  ese 
results show that miR-21 is an oncogenic miRNA that 
plays an important role in tumorigenesis. Th  e authors 
also found that antagonizing miR-21 caused apoptosis in 
MCF-7 cells, which was associated with lower expression 
of Bcl-2 protein in the anti-miR-21-transfected MCF-7 
cells and also in tumors derived from these cells, 
suggesting that Bcl-2 may be an indirect target of miR-21. 
To further elucidate the molecular mechanisms that 
regulate the function of miR-21, proteomic analysis of 
the above-mentioned xenograft tumors revealed that the 
tumor suppressor protein tropomyosin 1 (TPM1), which 
is known to be downregulated in breast cancer epithelial 
cell lines, was a target of miR-21 [64]. In the context of 
breast cancer, miR-21 has also been shown to inhibit the 
expression of the tumor suppressor PDCD4 (program-
med cell death-4). Although depletion of PDCD4 protein 
in MCF-7 cells by PDCD4 siRNA had no eﬀ  ect on cellular 
proliferation, it signiﬁ  cantly alleviated the anti-proliferative 
eﬀ  ect of miR-21 inhibition, underscoring an essential role 
for PDCD4 as a mediator of the biological eﬀ  ects  of 
miR-21 in breast cancer cells [65]. Another important 
target of miR-21 is the tumor suppressor gene phosphatase 
and tensin homolog (PTEN) [66]. In addition to TPM1 and 
PDCD4, one study also identiﬁ  ed Maspin as a direct target 
of miR-21 [67]. Th   ese three genes were shown to reduce 
invasiveness of a metastatic breast cancer cell line [64]. 
Th  eir ﬁ  ndings further establish miR-21 as an oncogenic 
miRNA and suggest that miR-21 has a role not only in 
tumor growth but also in invasion and tumor metastasis 
by targeting multiple anti-metastatic genes.
miR-155
miR-155 is over-expressed in a number  of human 
malignancies, including breast cancer [28,62]. A recent 
study has shown that miR-155 is upregulated in normal 
mouse mammary gland epithelial cells (NMuMG cells) 
by the TGF-β/Smad4 pathway and mediates TGF-β-
induced EMT and cell invasion [68]. To investigate the 
role of miR-155 in TGF-β-induced EMT, the authors 
found that ectopic expression of miR-155 in NMuMG 
cells disrupted proper tight junction formation and 
promoted  cell migration and invasion. Conversely, 
antagonizing miR-155 in NMuMG cells reduced  the 
occurrence of TGF-β-induced EMT and cell migration 
and invasion. miR-155 directly inhibited the expression 
of RhoA, a gene that regulates many cellular processes, 
including cell adhesion, motility, and polarity, and is an 
important modulator of cell junction formation and 
stability. Importantly, miR-155-induced phenotypes were 
restored by expressing a miR-155 insensitive version of 
RhoA in miR-155 overexpressing cells. Th  ese ﬁ  ndings 
suggest that miR-155 is regulated by the TGF-β/Smad4 
pathway and downregulates RhoA protein expression to 
drive EMT progression. Th   ey further demonstrated that 
miR-155 is associated with cancer invasiveness in human 
primary breast carcinoma by showing that miR-155 is 
highly expressed in invasive tumors but not in 
noninvasive  cancer tissues. Th  ese  results implicate 
miR-155 in EMT and invasion as observed in NMuMG 
cells and suggest that miR-155 may play a critical role in 
breast cancer metastasis.
miR-10b
miR-10b was the ﬁ   rst miRNA found to inﬂ  uence  the 
metastatic potential of human cancer cells [69]. Unlike 
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miR-10b was highly expressed only in metastatic cancer 
cells and was found to promote cell migration and invasion 
in vitro and initiate tumor invasion and metastasis in vivo. 
Expression of miR-10b was found to be induced by the 
transcription factor Twist; in turn, miR-10b inhibits the 
translation of the transcription factor homeobox D10 
(HOXD10), resulting in a cascade of cellular alterations 
that include expression of the prometastatic gene RHOC 
(ras homologue gene family member C), a gene that 
promotes cancer cell migration and invasion.
miR-373/520c family
miRNAs of the miR-373/520c family were identiﬁ  ed [60] 
as prometastatic using a forward genetic screen involving 
overexpression of almost 450 miRNAs in a non-
metastatic human breast cancer cell line (MCF-7 cells). 
MCF-7 cells were transduced with these miRNAs and 
subjected to a trans-well cell migration assay to identify 
miRNAs that stimulate cell migration. Th   e authors found 
that miR-373 and miR-520c promoted cancer cell 
migration and invasion in vitro and in vivo. Th  ey also 
showed that some cancer cell lines required miR-373 for 
migration and that these miRNAs elicited a migratory 
phenotype by inhibiting expression of the metastasis 
repressor CD44. Importantly, ectopic overexpression of 
CD44 without its 3´ UTR signiﬁ   cantly reduced the 
migra  tion of MCF-7 cells that express miR-373 or miR-
520c, suggesting that downregulation of CD44 is required 
for the migration phenotype of MCF-7 cells expressing 
miR-373 and miR-520c. Finally, the authors showed that 
miR-373 was upregulated whereas CD44 was decreased 
in clinical breast cancer metastasis samples, further 
implicating its role in breast cancer metastasis.
Gene interaction network for breast cancer miRNA 
targets
Th  e above-mentioned investigations on miRNAs impli-
cated in breast cancers substantially advance our 
knowledge about the roles of speciﬁ  c miRNAs in breast 
cancer development and metastasis. It is clear that each 
of these miRNAs inhibit the expression of many genes, 
Figure 1. Gene interaction network analysis of miRNA targets in breast cancer. Determined using Ingenuity software, the direct interaction 
network of 34 published targets of 11 miRNAs implicated in breast cancer pathogenesis is shown: miR-206 (grey), miR-17-5p (blue), miR-125a/b 
(cyan), miR-200 (dark green), let-7 (green), miR-34 (yellow), miR-31 (orange), miR-21 (pink), miR-155 (red), and miR-373/520c (maroon). The targets 
form a highly connected network centered on MYC. Arrows indicate protein-protein or protein-DNA interactions, suggesting these targets 
coordinate the expression and/or function of one another.
O’Day and Lal Breast Cancer Research 2010, 12:201 
http://breast-cancer-research.com/content/12/2/201
Page 7 of 10suggesting that comprehensive regulation can be achieved 
by antagonizing or over-expressing a single miRNA. 
Moreover, concomitant deregulation of these miRNAs 
would consequently alter the expression of many genes, 
thereby inducing tumorigenesis.
To better understand how the functions of these 
experimentally validated breast cancer miRNAs and their 
gene targets might be integrated within the pathogenesis 
of breast cancer, we have performed a gene interaction 
network analysis (Figure 1) similar to our previous study 
[70]. To do this, we generated a list of 34 genes known to 
be altered by the 11 miRNAs discussed above. Among 
these genes, 19 formed a well-connected gene interaction 
network in which MYC, a target of miR-34a, was the 
central node (10 connections). Other highly interacting 
genes were BCL-2, E2F1, CCND1 and ESR1, with seven, 
seven, seven and six interactions, respectively.
Th  ese results suggest that breast cancer is associated 
with changes in the expression of multiple miRNAs that, 
in turn, disrupt a network of genes that either activate or 
inhibit each other’s transcription or interact directly via 
protein-protein interactions. For instance, down  regula-
tion of miR-206 would enhance ESR1 expression, 
consequently increasing MYC transcription. MYC 
protein will be further elevated since loss of miR-34a 
would enhance its translation. Since CCND1, E2F1 and 
E2F3 are known to be activated by MYC, increased MYC 
would in turn enhance their expression. Moreover, down-
modulation of miR-17-5p (regulates CCND1 and E2F1) 
and miR-34a (regulates E2F3, CCND1 and CDK6) would 
further elevate levels of these proteins. Our ﬁ  ndings 
suggest that decreased expression of multiple tumor 
suppressor miRNAs leads to enhanced transcription and 
translation of these oncogenes in breast cancer via direct 
or indirect mechanisms.
Th   e role of oncogenic or metastasis-promoting 
miRNAs is also important. For example, increased levels 
of miR-21, miR-31 and miR-373/520c would ensure that 
the protein synthesis of TPM1 (regulated by miR-21), 
CD44 (regulated by miR-373/520c), and MMP16 
(regulated by miR-31) is repressed in breast cancer cells. 
In most cases, the protein encoded by a gene is up- or 
downregulated due to increased/decreased transcription 
and translation. Th  us, tumor suppressor or oncogenic 
miRNAs regulate the transcription of some of these 
genes by targeting transcription factors and also provide 
an additional layer of regulation by regulating their trans-
lation. Although many of these gene regulatory events 
will likely occur at diﬀ  erent stages of tumorigenesis and 
metastasis, it is clear that loss of miRNA regulation leads 
to a cascade of events that alter gene interaction networks 
important for breast cancer progression.
In addition to the above mentioned miRNAs, several 
other miRNAs, including miR-7, miR-128a, miR-210, 
miR-27b, miR-335, miR-126, miR-145 and miR-27a, have 
also been implicated in breast cancer. Uncovering the 
genes under the control of these miRNAs and how they 
integrate into the breast cancer gene interaction network 
will further aid our understanding of the disease. Further-
more, miRNA proﬁ   ling is emerging as a powerful 
diagnostic tool to characterize features of diﬀ  erent tumor 
types. Th   is has been particularly useful in breast cancer, 
as miRNA signatures can unequivocally distinguish normal 
and malignant breast tissue and discriminate between 
breast cancer subtypes [71].
Conclusion
Th  e usefulness of miRNA-based breast cancer therapy 
has been explored by these emerging studies that high-
light their importance in breast cancer. A better 
understanding of the network of genes and cellular 
pathways regulated by these miRNAs will undoubtedly 
enable us to understand breast cancer pathogenesis and 
therapy. To accomplish this, identifying the genome-wide 
targets of these miRNAs is essential. Moreover, it is yet to 
be seen how these breast cancer-associated miRNAs will 
move from the laboratory bench into a clinical setting for 
the treatment of breast cancer. In this regard, the delivery 
of miRNA inhibitors or miRNA mimics speciﬁ  cally to 
tumor cells is one of the greatest challenges. Viral vector 
systems seem to be a reasonable option for eﬃ   cient and 
organ-speciﬁ  c delivery [72], and it is likely that miRNA-
based therapeutics will become a reality in the near 
future.
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